Lifestyle Features

BioNTech's mRNA cancer therapy misses first goal in head and neck trial

Reuters  |  Updated Oct. 13 - 11:48 a.m.  |  Save Story

BioNTech said on Tuesday its experimental mRNA cancer immunotherapy ​failed to meet the first main goal of a mid-to-late-stage trial in patients with head ‌and neck cancer.

Agilent to buy pathology software maker Proscia for $240 million

Reuters  |  Updated Oct. 13 - 11:05 a.m.  |  Save Story

Agilent Technologies said on Tuesday it ​would acquire pathology software maker Proscia for $240 million in cash, plus ‌up to $30 million tied to future performance targets, ⁠as the laboratory ​equipment maker expands ⁠its push into AI-enabled diagnostics.

Bumble swipes right on $1.3 billion go-private deal amid online dating industry reset

Harshita Mary Varghese and Jaspreet Singh, Reuters  |  Posted Oct. 13 - 10:34 a.m.  |  Save Story

Bumble said on Tuesday it had agreed to be taken private by Ithaca Holdings in a ​deal valued at $1.3 billion, as the dating app pushes forward with its months-long turnaround amid shifting Gen Z dating habits and declining paying users.

Roche strikes obesity drug licensing deal worth up to $1.16 billion with Chinese Rona Therapeutics

Reuters  |  Updated Oct. 13 - 8:08 a.m.  |  Save Story

Swiss drugmaker Roche entered ​a licensing agreement worth up to $1.16 billion with Rona ‌Therapeutics for its investigational obesity drug candidate, ⁠the Chinese ​biotech firm said ⁠on Tuesday.

A forgotten history of widescreen movies

VideoPeter Rosen, KSL  |  Updated Oct. 13 - 7:21 a.m.  |  Save Story

A Virginia inventor's early widescreen film technology helped pave the way for modern cinema, and his descendants are working to ensure his contributions to Hollywood history are recognized.

Bristol Myers' lung disease drug succeeds at lower dose in late-stage trial

Padmanabhan Ananthan, Reuters  |  Updated Oct. 13 - 5:48 a.m.  |  Save Story

Bristol Myers Squibb said on Monday a lower dose of its ​experimental drug slowed the progression of a serious lung-scarring disease, putting it on track to be a first-of-its-kind treatment if approved.

Pope Leo leaves Vatican for hospital ahead of surgery on lung nodule

Reuters  |  Posted Oct. 13 - 5:02 a.m.  |  Save Story

Pope Leo left ​the Vatican on Tuesday in a convoy of vehicles ‌ahead of his expected admission to Rome's ⁠Gemelli hospital ​for surgery to ⁠remove a small growth ‌found on one ‌of his lungs, the first ⁠major health ⁠issue of his 17-month tenure.

Pennsylvania coroner reports measles death, toll rises to six

Reuters  |  Updated Oct. 12 - 2:11 p.m.  |  Save Story

Pennsylvania's Franklin County coroner on Monday reported a measles-associated death in a 39-year-old woman with several ​health conditions, the state's sixth death linked to the disease.

Bausch + Lomb CEO Saunders departs, Chairman Appio named interim chief

Kunal Das, Reuters  |  Updated Oct. 12 - 9:54 a.m.  |  Save Story

Bausch + Lomb said on Monday that CEO Brent ​Saunders will leave the eye-care company by mutual agreement with its board, sending its US-listed shares down more ‌than 7%.

Bristol Myers radiopharma cancer drug slows rare tumor progression in study

Siddhi Mahatole, Reuters  |  Updated Oct. 12 - 8:07 a.m.  |  Save Story

Bristol Myers Squibb said on Monday its experimental radiopharmaceutical cancer therapy ​significantly delayed disease progression in patients with rare, advanced gastrointestinal and pancreatic tumors that had progressed after earlier treatment.

Steris doubles down on healthcare consumables with $2.1 billion Xodus buy

Christy Santhosh, Reuters  |  Updated Oct. 12 - 7:35 a.m.  |  Save Story

Medical equipment maker Steris will buy privately held Xodus ​Medical for $2.1 billion, adding surgical products designed to improve safety for patients and operating-room staff to its healthcare consumables business.

Bristol Myers therapy slows rare tumor progression, bolstering radiopharma push

Siddhi Mahatole, Reuters  |  Posted Oct. 12 - 7:09 a.m.  |  Save Story

Bristol Myers Squibb said on Monday its experimental radiopharmaceutical therapy significantly delayed disease ​progression in patients with rare, advanced gastrointestinal and pancreatic tumors that had progressed after earlier treatment.

Gen Z is feeling nostalgic. Experts say it might be a good thing

Emily Walker, Deseret News  |  Posted Oct. 12 - 6:20 a.m.  |  Save Story

In a recent national survey, 68% of Gen Z respondents reported feeling nostalgic for eras before their lifetime, while 73% said they were drawn to the era's styles, media and hobbies.

Halloween spider web decorations can trap and kill bats, experts warn

Kayla Moeller, KOVR  |  Posted Oct. 11 - 10:49 a.m.  |  Save Story

Fake spider webs may be a popular Halloween decoration, but wildlife experts are warning that the stretchy material can trap and kill bats, birds and other animals.

BRIEF

Taylorsville event gathers winter coats, Halloween costumes for families in need

Allison Lyons, KSL  |  Posted Oct. 11 - 10:11 a.m.  |  Save Story

Hundreds gathered in Taylorsville for the "Coats, Costumes, Cookies and Cocoa" event, not letting the rainy weather stop them.

US FDA approves Asahi Kasei's drug for persistent herpes infections

Reuters  |  Updated Oct. 9 - 11:57 a.m.  |  Save Story

The US FDA on Friday approved Japan's Asahi Kasei's ​drug for persistent herpes simplex virus sores in certain patients with weakened immune systems who have ‌not responded to available antiviral treatments.

Teva wins FDA approval for monthly schizophrenia injection Weltruza

Reuters  |  Updated Oct. 9 - 11:45 a.m.  |  Save Story

(Corrects sourcing in bullet 3, updates share reaction in ​bullet point 5)

Health Rounds: Blindness treatment based on Nobel-winning research shows promise

Nancy Lapid, Reuters  |  Updated Oct. 9 - 7:49 a.m.  |  Save Story

(This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays.)

Argenx discontinues Vyvgart study in Sjögren's disease, shares tumble

Reuters  |  Updated Oct. 8 - 2:48 p.m.  |  Save Story

Argenx said on Thursday it had discontinued ​a late-stage study of its efgartigimod drug in adults with Sjögren's disease, an autoimmune ‌condition that damages the glands producing tears and saliva, ⁠putting its shares ​on track for their ⁠biggest one-day fall in almost three ‌years.